natgillin/translations-raw huggingface dataset:
The shampoo or conditioner of any of paragraphs 58-66, further comprising one or more pharmaceutically acceptable excipients, wherein the one or more excipients are selected from the group consisting of water, surfactants, vitamins, natural extracts, preservatives, chelating agents, perfumes, preservatives, antioxidants, chelating agents, hair coloring agents, proteins, amino acids, humectants, fragrances, emollients, penetrants, thickeners, viscosity modifiers, hair fixatives, film formers, emulsifiers, opacifying agents, propellants, liquid vehicles, carriers, salts, pH adjusting agents, neutralizing agents, buffers, hair conditioning agents, anti-static agents, anti-frizz agents, anti-dandruff agents, and combinations thereof. 
HR P20171408 T1 Komplet prema bilo kojem od zahtjeva 43-50, naznačen time da druga formulacija nadalje sadrži jedno ili više kozmetički prihvatljivih pomoćnih sredstava odabranih iz skupine koju čine voda, površinski aktivna sredstva, vitamini, prirodni ekstrakti, konzervansi, kelirajuća sredstva, parfemi, sredstva za održavanje, antioksidansi, sredstva za kelatiranje, sredstvo za bojenje kose, proteini, aminokiseline, sredstva za vlaženje, mirisi, emolijenti, sredstva za prodiranje, sredstva za zgušnjavanje, modifikatori viskoziteta, učvršćivači za kosu, sredstva koja tvore film, emulgatori, sredstva za zamućivanje, propelanti, tekuća sredstva, nosači, soli, sredstva za podešavanje pH, sredstva za neutralizaciju, puferi, regeneratori, antistatička sredstva, sredstva protiv kovrčanja, sredstva protiv prhuti i njihove kombinacije.
In this embodiment, the perforating device 140 is a Hydra-Jet® tool, which is available from Halliburton Energy Services, Inc. 
Halliburton Energy Services, Inc., P.O. Box 1431, 73536 Duncan, OK, US (72) Izumitelji:
A person of ordinary skill in the art will have no difficulty, considering that skill and this disclosure (including the Examples), in preparing compounds of the first and fifth aspects of this invention. 
Stručna osoba neće imati teškoća, razmatrajući stručnost 1 ovo razotkrivanje (uključujući primjere izvođenja), u pripravljanju spojeva prvog i petog aspekta ovog izuma, upotrebu spojeva i postupaka.
mM MgCl2 GDP Buffer: binding buffer plus GDP, ranging from 0.4 to 40 µM, make fresh before assay 
10 mM MgC1, GDP pufer: vezivni pufer plus GDP, raspona od 0.4 do 40uM, svježe pripremljeno prije ispitivanja
A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 which is selected from the group consisting of: 
Derivat pirimidona, ili njegova sol, ili njegov solvat ili njegov hidrat, u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine:
A compound according to any one of claims 1 to 8 wherein each aryl independently may be phenyl optionally substituted with C1-6alkyl, amino, mono- or diC1-6alkyl-amino, C1-6alkyloxy, aminosulfonyl, Het, the latter more in particular being thiadiazolyl 
Spoj prema bilo kojem od zahtjeva 1 do 8 naznačen time da svaki aril nezavisno može biti fenil po izboru supstituiran sa C,.galkil, amino, mono- ili diC, galkil-amino, C, galkiloksi, aminosulfonil, Het, potonji je posebice tiadiazolil.
Studies using A2A knockout mice suggest that these animals show a blunted response to psychostimulants such as amphetamine and cocaine, despite the fact that their expression and binding affinities of D1 and D2 receptors are unaffected (Chen et al., 2000, Neurosci 97:195-204). 
Studije koje koriste miševe kod kojih je izbačen A,,-receptor sugeriraju da te životinje pokazuju tup odgovor na psihostimulanse poput amfetamina i kokaina, unatoč činjenici da njihova ekspresija i afinitet vezanja na D,; i D, receptore je netaknuta (Chen et al., 2000, Veurosci 97: 195-204).
Certain specific embodiments provided herein describe a compound of formula (I-K): 
Spoj sukladno patentnom zahtjevu 3, formule (I-K): Kore g
A method for inhibiting arthritis in a mammal in need thereof, comprising administrating to the mammal an effective amount of a mixture comprising (a) hyaluronic acid and (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, wherein the mixture comprises about 85 wt % to about 99.5 wt % of hyaluronic acid and about 0.5 wt % to about 15 wt % of the HMG-CoA reductase inhibitor, based on the total weight of hyaluronic acid and the HMG-CoA reductase inhibitor. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da obuhvaća hijaluronsku kiselinu od oko 85 masenih % do oko 99,5 masenih % i inhibitor reduktaze HMG-CoA od oko 0,5 masenih % do oko 15 masenih %, na temelju ukupne mase hijaluronske kiseline i inhibitora reduktaze HMG-CoA.
A composition based on ubidecarenone, or coenzyme Q10 or CoQ10, comprises CoQ10, one or more specific hydrophylic carriers selected from the maltodextrins class and one or more adjuvant agents selected from the sucrose-esters class. RELATED APPLICATIONS 
Ternarni pripravak baziran na ubidekarenonu, ili koenzimu Q10 ili CoQ10, naznačen time da se sastoji od tri komponente ili razreda komponenata: od CoQ10, od jednog ili više specifičnih hidrofilnih nosača odabranih iz razreda maltodekstrina i jednog ili više pomoćnih sredstava odabranih iz razreda sukroza-estera.
A pharmaceutical composition in which the chimeric peptide mentioned in claim 7 or a pharmaceutically acceptable salt thereof is an effective ingredient. 
Farmaceutski pripravak, naznačen time, da je kimerni peptid u skladu s patentnim zahtjevom 1 ili 2 ili njegove farmaceutski prihvatljive soli, djelotvorni sastojak.
The compound for use of claim 5, which is: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 
[image] [image] ili njena farmaceutski prihvatljiva sol, solvat ili njen stereoizomer. [image] Tvar za uporabu u skladu s patentnim zahtjevom 6, koja je:
Examples of preferred full length heavy chain amino acid sequences of antibodies of the invention are shown in SEQ ID NO:75-78 respectively. 
(c) varijabilno područje jakog lanca CDR3 aminokiselinske sekvence odabrane iz skupine koju čine od SEQ ID NO: 16 do SEQ ID NO:21; 1
The compounds of this invention inhibit HIV integrase. 
Spojevi ovog izuma inhibiraju HIV integrazu.
The pharmaceutical composition of claim 18 further comprising at least one additional therapeutic agent selected from the group consisting of interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, mevalonate decarboxylase antagonists, antagonists of the renin-angiotensin system, other anti-fibrotic agents, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophillin inhibitors, HCV IRES inhibitors, pharmacokinetic enhancers, and other drugs for treating HCV. 
Farmaceutski pripravak prema zahtjevu 18, naznačen time, da nadalje sadrži barem jedno dodatno terapeutsko sredstvo izabrano iz skupine koja obuhvaća interferone, ribavirine 1 njihove analoge, inhibitor HCV NS3 proteaze, inhibitori Ns5a, alfaglukozidaza 1 inhibitore, hepatoprotektante, mevalonat dekarboksilaza antagoniste, renin-angiotenzin, druga protufibrotička sredstva, nukleozidne ili nukleotidne inhibitore HCV NSS5B polimeraze, ne-nukleozidne inhibitore HCV NSS5B polimeraze, inhibitore HCV NSSA, TLR -7 agoniste, ciklofillin inhibitore, HCV IRES inhibitore, farmakokinetičke pojačivače 1 druge lijekove za liječenje HCV.
At least one bacteriophage resistant variant strain obtained using the method of para 1. 
Starter kultura naznačena time da se dobiva pomoću postupka prema zahtjevu 1.
A lateral pipe adaptor as claimed in claim 11 wherein the one or more shims have a groove provided on the surface of their outer end. 
Adapter za bočne cijevi (1) u skladu s patentnim zahtjevom 10, naznačen time što jedna ili više podložnih pločica (50) imaju utor (51), načinjen na površini svog vanjskog kraja.
Use according to claim 12, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 2400 mg/day for a time period. 
Upotrcba prema zahtjevu 12, gdje je prije stupnja (a), spomenutom pacijentu davan pirfenidon u dozama nižim od 2400 mg/dan u tijeku vremenskog perioda.
The phases were separated and the aqueous phase was extracted with ethyl acetate. 
Faze se razdijele i vodena faza se ekstrahira sa etil acetatom.
The process according to claim 1, wherein the salt of compound of Formula (IV) is an inorganic or organic salt, selected from the group consisting of halide, phosphate, phosphite, carbonate, bicarbonate, sulphate, bisulfate, hydroxide, nitrate, persulfate, sulfite, sulphide, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, and cholate. 
Postupak prema zahtjevu 1, naznačen time da je sol spoja prema formuli (IV) anorganska ili organska sol, odabrana iz skupine koja se sastoji od halida, fosfata, fosfita, karbonata, bikarbonata, sulfata, bisulfata, hidroksida, nitrata, persulfata, sulfita, sulfida, acetata, askorbata, benzoata, citrata, dihidrogen citrata, hidrogen citrata, oksalata, sukcinata, tartrata, taurokolata, glikokolata i kolata.
means for continuously feeding black water and grey water from said at least one collection tank to said primary treatment unit; 
sredstvo za kontinuiranu dopremu crne vode i sive vode iz navedenog najmanje jednog sabirnog spremnika u navedenu jedinicu za primarnu obradu;
an anti-cancer agent. 
(b) protutumorsko sredstvo.
The method of claim 17, wherein ADCC activity is determined using Ba/F3 cells expressing FGFR2IIIb as target cells and isolated human PBMCs as effector cells. The method of claim 1, wherein the afucosylated antibodies have enhanced affinity for Fc gamma RIIIA compared to a fucosylated anti-FGFR2IIIb antibody having the same amino acid sequence. 
Pripravak za uporabu prema zahtjevu 6, naznačen time što afukozilirana protutijela imaju povećani afinitet za Fc gama RIIIA u usporedbi s fukoziliranim anti-FGFR2IIIb protutijelom koje ima istu sekvencu aminokiseline i Fc gama RIIIA se bira od Fc gama RIIIA (V158) i Fc gama RIIIA (F158).
Ra and Rb together are (CH2)n where n is 3 or 4, to form, with the pyrimidine ring carbon atoms to which they are attached, a fused 5-or 6-membered carbocyclic ring; and 
R* i R' zajedno su (CH), gdje n je 3 ili 4, da bi formirali, s ugljikovim atomima pirimidinskog prstena za koji su vezani, kondenzirani 5-ili 6-člani karbociklički prsten; 1
The compound of claim 13, comprising the modified oligonucleotide covalently linked to a conjugate group. 
Spoj prema zahtjevu 7, koji sadrži modificirani oligonukleotid kovalentno vezan s konjugiranom grupom.
separating the calcium carbonate particles by removing the particles comprising components other than calcium carbonate by means downstream of a detection area and controllable by computer-controlled evaluating means as a function of sensor signals resulting from radiation penetrating a flow of said particles, said radiation being emitted by an X-ray source and captured in at least one sensor means, wherein the X-radiation is permitted to pass at least two filter devices in relation to mutually different energy spectra positioned upstream of the at least one sensor means and sensor lines with sensor means, a sensor line being provided for each of the at least two filters. The separation step is advantageously carried out in a device according to WO 2005/065848, the disclosure of which herewith is explicitly included. 
- < eparacije čestica kalcijevog karbonata uz uklanjanje čestica koje sadrže druge komponente osim kalcijevog karbonata pomoću sredstava nizvodno od područja detekcije koja se nadziru pomoću računalno upravljanih sredstava za procjenu funkcije senzorskih signala koji proizlaze iz zračenja koje prodire u tok navedenih čestica, a navedeno zračenje je emitirano pomoću izvora X-zraka i hvata se u barem jednom senzorskom elementu, pri čemu je X-zračenju omogućeno da prođe barem dva filterska uređaja u odnosu na međusobno različite energetske spektre smještene uzvodno od barem jednog senzorskog elementa i senzorske linije sa većim brojem pojedinačnih piksela koji su smješteni poprečno na tok čestica kao senzorski elementi, a senzorska linija je predviđena za svaki od barem dva filtera.
The portion capsule according to claim 1, wherein the filter element is attached to the collar edge by ultrasound. 
Kapsula s porcijom (1) prema jednom od prethodnih zahtjeva, naznačena time da je element filtera (7) konfiguriran tako da bude elastičan.
The product was obtained by analogy with the method described in example 1(step1.6) and using ethyl 3-amino-3-(2-aminoethyl)pyrrolidine-1-carboxylate hydrochloride (2:1) 
Produkt se dobije postupkom analognim onom opisanom u primjeru 1 (korak 1.6), uz upotrebu hidroklorida etil-3-amino-3-(2-aminoetil)pirolidin-1-karboksilata (2:1).
The boat hull according to claim 2, wherein forward portions of said first and opposite dual circular curved hull outer surface areas (12, 12M) converge at the plane of symmetry (PS) forward of the beam plane (PB). 
Trup broda u skladu s patentnim zahtjevom 2, naznačen time, da se prednji dijelovi navedene prve i suprotne vanjske površine prvog dvostrukog kružno zakrivljenog trupa (12, 12 M) spajaju u ravnini simetrije (PS) ispred ravnine nosača (PB).
Generally it is preferred to use a compound of formula (I) in the form of a purified single enantiomer. 
Općenito je poželjno upotrijebiti spoj formule (Ia), (Ib) ili (Ic) u obliku pročišćenog pojedinačnog enantiomera.
A quantity of 1000 g 1,1,1,2,3,3,3 heptafluoropropane (=HFA 227) is cooled down at a temperature of −55° C. and, while stirring, mixed with a solution of 11.7 g polyoxethylene-25-glyceryl-trioleate (trade name: Tagat TO) in 11.7 g absolute ethanol. 
Količina od 1000g 1,1,1,2,3,3,3 heptafluoropropana (= HFA 227) se ohladi na temperaturu od -55C i uz miješanje pomiješa s otopinom od 11,7 g polioksetilen-25-gliceril-trioleata (trgovačko ime: Tagat TO) u 11,7 g apsolutnog etanola.
the second CRISPR RNA recognition sequence and the fourth CRISPR RNA recognition sequence are separated by about 25 bp to about 1 kb. 
drugi CRISPR RNA sekvenca prepoznavanja i četvrti CRISPR RNA sekvenca prepoznavanja su odvojeni su za oko 25 bp do oko 1 kb; i / ili
R30A and R31A are independently selected from the group consisting of hydrogen, an optionally substituted C1-24-alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl and an optionally substituted C3-6 cycloalkenyl; 
A i R31A su neovisno odabrani iz skupine koja sadrži vodik, po izboru supstituiran C1-24-alkil, po izboru supstituiran C2-24 alkenil, po izboru supstituiran C2-24alkinil, po izboru supstituiran C3-6 cikloalkil i po izboru supstituiran C3-6 cikloalkenil;
The antibody or a functional fragment of the antibody according to any one of claims 1 to 16, comprising a first and a second heavy chain, wherein the first and the second heavy chain are each independently selected from the following (i) to (iii): 
Antitijelo ili funkcionalni fragment antitijela prema bilo kojem od patentnih zahtjeva 1 do 16, koje sadrži prvi i drugi teški lanac, gdje prvi i drugi teški lanac su svaki nezavisno odabrani od sljedećih (1) do (111):
n means an integer selected from 1, 2, 3, 4, 5 and their salts, solvates or salts of solvates. 
R* je hidroksil skupina, klorov atom, -S-CH:, -S-CH>-CH., -O-CH., ili -O-CH,-CHz; i njihove soli, solvati ili soli solvata.
The intragastric balloon of claim 1, wherein, once the foam has cured, the intragastric balloon is adapted to maintain its shape if punctured. 
Intragastrični balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu se, nakon što pjena očvrsne, intragastrički balon prilagodi zadržati oblik ako je probijen.
A method of deploying and supporting a flexible object (7) with the apparatus of any of claims 1-11, the method comprising: providing the elongate support (3; 103; 203) having the longitudinal first guide (4; 104; 204); 
Postupak postavljanja i podržavanja savitljivog predmeta (7) uređajem opisanim u bilo kojem od patentnih zahtjeva 1 do 11, naznačen time da se postupak sastoji od: pružanja izduljenog oslonca (3; 103; 203) koji sadrži prvu uzdužnu vodilicu (4; 104; 204);
The IL-18BP that is produced by using the medium of the present invention is preferably glycosylated. 
Poželjno je da je IL-18BP proizveden uz uporabu medija predstavljenog izumom glikoziliran.
The pharmaceutical composition according to claim 1, wherein said CCBs is selected from the group consisting of amlodipine, barnidipine, felodipine, isradipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, diltiazem, gallopamil, and verapamil. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni CCB odabran iz skupine koju čine amlodipin, barnidipin, felodipin, izradipin, lacidipin, lerkanidipin, manidipin, nikardipin, nifedipin, nimodipin, nisoldipin, nitrendipin, diltiazem, galopamil i verapamil.
An antibody of any one of claims 1 to 14, a conjugate of claim 16 or a pharmaceutical composition of claim 17 for use in a method of treating or preventing a disease or disorder involving cells expressing CLD18. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 20, konjugat prema patentnom zahtjevu 22 ili farmaceutska kompozicija prema patentnom zahtjevu 23 za uporabu u postupku liječenja ili prevencije bolesti ili poremećaja koja/koji uključuje stanice koje eksprimiraju CLD18A2.
converting the suspension of step (1) into particulate form; 
(2) prevođenja suspenzije iz koraka (1) u partikularni oblik;
A dispenser according to clause 3, wherein the engaging portion on the first ring member comprises a plurality of teeth on an inner circumferential surface of the first ring member. 
Dispenzer u skladu sa patentnim zahtjevom 20, gdje dio (1630) za angažiranje na prvom prstenastom elementu (202, 1610) sadrži veliki broj zuba, na unutarnjoj perifernoj površini prvog prstenastog elementa.
Nalmefene according to any of claims 1-3, wherein said patient is subject to counseling focused on enhanced treatment adherence and reduced alcohol consumption. 
Nalmefen za uporabu prema bilo kojem od zahtjeva 1-2, gdje navedeni bolesnik prolazi savjetovanje s fokusom na poboljšanje pridržavanja terapije i smanjenje konzumacije alkohola.
possibly a strength of at least 10 cN/tex, preferably at least 20 cN/tex, and/or 
modula elastičnosti od barem 1,000 cN/tex, preporučljivo od barem 1,300 cN/tex.
is CH2 or O, said compound of formula XIX is then converted to the compound of formula XX wherein A1, A2, A3, X1, X2, L1, R1 and n are as defined above, and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is then reacted with a compound of formula III G-A4b-L0 (III), wherein 
F yi (xx) gdje su Al, A2, A3, X1, X2, LI, R1 in definirani kao gore; i kada je LI nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat zatim reagira sa spojem formule III
The method according to claim 9, in which said tissue infarct is selected from the group consisting of cardiac and cerebral infarction. 
Primjena prema zahtjevu 20, kod kojo je infarkt tkiva izabran iz grupe koja se sastoji od srčanog i cerebralnog infarkta.
and R8′ together with the carbon atom to which they are attached form C3-C7cycloalkyl; 
R* je vodik, Cy-Cyalkil, benzil; ili i R* zajedno sa atomom ugljika na koji su vezani tvori C3-C;cikloalkil;
A freezing mould bag (110) including: two sheet-like film pieces (12, 14) having substantially the same geometrical shape and defining an outer, substantially rectangular periphery with two sides, a bottom and a top; 
dva komada (12, 14) filma u vidu listova koji imaju u osnovi isti geometrijski oblik i definiraju vanjski u osnovi pravokutni obujam vrećice sa dvije strane, dnom i vrhom;
Cy is a phenyl group, wherein the phenyl group may have one to three substituents, which may be the same or different, selected from the group consisting of a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group and a C2-6 alkanoyl group. 
Cy je fenilna skupina, pri čemu fenilna skupina ili piridilna skupina može imati jednog do tri supstituenta, koji mogu biti jednaki ili različiti, izabrani iz skupine koja se sastoji od atoma halogena, C;4 alkilne skupine, i C2g alkanoilne skupine.
The method according to claim 13 or 14, wherein the disorder is schizophrenia. 
Terapija prema zahtjevu 9, naznačena time da neurološki 1 psihijatrijski poremećaj je shizofrenija.
Methods of treatment, and administration of the vaccine 
Datum podnošenja europske prijave patenta:
A combination of (a) a compound of Formula (Ia) or (Ib) as defined in any one of claims 1 to 15, and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents, wherein the combination is for use in the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection. 
17. Kombinacija (a) spoja sa Formulom (Ia) ili (Ib) kako je definirano u bilo kojem zahtjevu od 1 do 15, 1 (b) jednog ili više drugih antibakterijskih sredstava uz uvjet da jedno ili više drugih antibakterijskih sredstava nisu antimikobakterijska sredstva, naznačena time da je kombinacija za uporabu kod liječenja bakterijske infekcije uz uvjet da bakterijska infekcija nije mikobakterijska infekcija.
A method of synthesizing a compound of claim 1 or optionally a salt thereof, comprising the step of reacting a compound having a structure represented by formula (II) with the compound having the structure represented by formula (III), wherein X is selected from -O-alkyl, -O-alkenyl, -O-alkynyl, -O-acyl, and halogen, particularly wherein X is -OEt; and, optionally, reacting the resultant compound with an acid to make an acid salt. 
Postupak sinteze spoja prema zahtjevu 1, ili po izboru njegove soli, koji obuhvaća korak reakcije spoja čija je struktura predstavljena formulom (II) sa spojem čija je struktura predstavljena formulom (III), [image] pri čemu se X bira između -O-alkil, -O-alkenil, -O-alkinil, -O-acil i halogena, posebno X je -OEt; i, po izboru, reakciju tako dobivenog spoja s kiselinom kako bi se dobila sol te kiseline.
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims. Netupitant or a pharmaceutically acceptable salt thereof, for use in treating chemotherapy induced nausea and vomiting ("CINV") induced by highly emetogenic chemotherapy, for a period of five consecutive days in a patient in need thereof, wherein said netupitant is administered in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases of emesis, enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK1 receptors in the striatum seventy-two hours after said administration. 
Netupitant ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju kemoterapijom inducirane mučnine i povraćanja ("CINV*") induciranog vrlo emetogenom kemoterapijom, tijekom razdoblja od pet uzastopnih dana kod potrebitog pacijenta, pri čemu se navedeni netupitant primjenjuje u terapijski učinkovitoj količini koja je učinkovita za liječenje mučnine i povraćanja tijekom akutne i odgođene faze emeze, ulazi u sustavnu cirkulaciju, prelazi krvno moždanu barijeru i zauzima najmanje 70% NK1 receptora u strijatumu sedamdeset i dva sata nakon primjene, pri čemu a) navedenom se pacijentu prvi dan daje prva doza deksametazona, pri čemu navedena prva doza obuhvaća od 50 do 70% najniže učinkovite doze kada se primjenjuje zasebno; 1 b) navedenom se pacijentu drugi, treći i četvrti dan daje druga doza deksametazona, pri čemu navedena druga doza obuhvaća od 40 do 60% najniže učinkovite doze kada se primjenjuje zasebno.